Skip to content
BiologicalX

Comparison

Low-Dose Naltrexone vs Testosterone

Side-by-side of Low-Dose Naltrexone and Testosterone. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Low-Dose Naltrexone

  • Off-label use at 1.5 to 4.5 mg, roughly one-tenth the FDA-approved 50 mg addiction-treatment dose
  • Proposed mechanisms include brief opioid receptor blockade triggering rebound endogenous opioid release, plus TLR4 antagonism
  • Compounded prescription only; insurance rarely covers; cash prices 20 to 80 USD per month
  • Younger 2013 reported ~30% pain reduction in fibromyalgia at 4.5 mg in a small crossover trial
  • Smith 2011 reported endoscopic improvement in active Crohn's disease (n=40 placebo-controlled)
  • Vivid dreams affect 20 to 40% in first 2 weeks; manageable by switching to morning dosing

Testosterone

  • Primary androgen; FDA approved for hypogonadism with confirmed deficiency and symptoms
  • Testosterone Trials (2016) showed sexual function and bone density improvements in older hypogonadal men
  • TRAVERSE 2023 (n=5,246) found non-inferiority on MACE versus placebo, with higher AF and PE rates
  • Schedule III controlled substance in US; WADA banned in sport
  • Aromatizes to estradiol; converts to DHT via 5-alpha reductase; both metabolites matter clinically
  • Erythrocytosis (HCT above 54%) affects 5 to 25% of users and is the most common dose-limiting effect

Side-by-side

Attribute Low-Dose Naltrexone Testosterone
Category pharmaceutical hormone
Also known as LDN, naltrexone (low dose) TRT, testosterone replacement therapy, testosterone cypionate, testosterone enanthate, Androgel, Testim
Half-life (hr) 4 192
Typical dose (mg) 4.5 150
Dosing frequency once daily, typically at bedtime weekly to twice-weekly (cypionate/enanthate IM or SC); daily (topical, oral); every 3 to 6 months (pellet)
Routes oral intramuscular, subcutaneous, topical, buccal, subcutaneous (pellet), oral
Onset (hr) 1 24
Peak (hr) 1.5 72
Molecular weight 341.4 288.42
Molecular formula C20H23NO4 C19H28O2
Mechanism Brief mu-opioid receptor antagonism proposed to trigger compensatory upregulation of endogenous opioids; secondary TLR4 antagonism on microglia and immune cells contributes to anti-inflammatory effect. Androgen receptor agonist driving anabolic gene transcription in muscle, bone, brain, and androgen-sensitive tissue. Aromatized to estradiol and 5-alpha-reduced to DHT, both with distinct downstream effects.
Legal status Off-label compounded prescription (naltrexone is FDA approved for opioid and alcohol use disorder at 50 mg) Schedule III controlled substance (US); WADA banned
WADA status allowed banned
DEA / Rx Rx only (not a controlled substance) Schedule III
Pregnancy Insufficient data; not routinely recommended Category X; contraindicated in pregnancy (virilizing effect on female fetus)
CAS 16590-41-3 58-22-0
PubChem CID 5360515 6013
Wikidata Q426444 Q150726

Safety profile

Low-Dose Naltrexone

Common side effects

  • vivid dreams
  • sleep disruption
  • headache
  • mild GI upset
  • fatigue (early)

Contraindications

  • concurrent opioid use
  • acute hepatitis or liver failure
  • opioid dependence
  • pregnancy (insufficient data)

Interactions

  • opioid analgesics (oxycodone, morphine, codeine): blocks analgesic effect; precipitates withdrawal in dependent users(major)
  • tramadol: blocks opioid component of analgesia(major)
  • thyroid hormone replacement: may alter dose requirements after immune modulation; monitor TSH(minor)

Testosterone

Common side effects

  • erythrocytosis
  • acne
  • oily skin
  • fluid retention
  • increased body hair
  • fertility suppression
  • injection-site reactions

Contraindications

  • active prostate cancer
  • active breast cancer
  • untreated severe sleep apnea
  • untreated severe BPH
  • uncontrolled heart failure
  • polycythemia at baseline

Interactions

  • warfarin: may potentiate anticoagulant effect; monitor INR(moderate)
  • insulin: may improve insulin sensitivity; monitor glucose in diabetics(moderate)
  • 5-alpha reductase inhibitors (finasteride): blocks DHT conversion; reduces some androgen effects(moderate)
  • aromatase inhibitors (anastrozole): lowers estradiol; risk of over-suppression(moderate)

Which Should You Take?

Testosterone comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Low-Dose Naltrexone is the right call when one of the conditionals below applies.

Edge case: Testosterone is contraindicated in pregnancy; Low-Dose Naltrexone is the safer pick if that applies.

Default choice: Testosterone. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Low-Dose Naltrexone only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Low-Dose Naltrexone and Testosterone?

Low-Dose Naltrexone and Testosterone differ in category (pharmaceutical vs hormone), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Low-Dose Naltrexone or Testosterone?

Low-Dose Naltrexone half-life is 4 hours; Testosterone half-life is 192 hours.

Can you stack Low-Dose Naltrexone with Testosterone?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper